Last reviewed · How we verify
MEDI6383 and MEDI4736 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
MEDI6383 and MEDI4736 (MEDI6383 and MEDI4736) — MedImmune LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MEDI6383 and MEDI4736 TARGET | MEDI6383 and MEDI4736 | MedImmune LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MEDI6383 and MEDI4736 CI watch — RSS
- MEDI6383 and MEDI4736 CI watch — Atom
- MEDI6383 and MEDI4736 CI watch — JSON
- MEDI6383 and MEDI4736 alone — RSS
Cite this brief
Drug Landscape (2026). MEDI6383 and MEDI4736 — Competitive Intelligence Brief. https://druglandscape.com/ci/medi6383-and-medi4736. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab